Back SAVE THE DATE! Joint EDQM-EPAA Symposium: “Pyrogen testing 2.0: Ethical, Evolving and Eco-friendly - Implementing safe, rapid, state-of-the-art and sustainable non-animal approaches worldwide”, 25-26 February 2026

EDQM Strasbourg, France 22/07/2025
  • Diminuer la taille du texte
  • Augmenter la taille du texte
  • Imprimer la page
  • Imprimer en PDF
SAVE THE DATE! Joint EDQM-EPAA Symposium: “Pyrogen testing 2.0: Ethical, Evolving and Eco-friendly - Implementing safe, rapid, state-of-the-art and sustainable non-animal approaches worldwide”, 25-26 February 2026

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is pleased to announce a symposium co-organised with the European Partnership for Alternative Approaches to Animal Testing (EPAA) entitled “

In February 2023, the EDQM and EPAA hosted a landmark conference to present the European Pharmacopoeia (Ph. Eur.) Commission’s strategy to phase out the rabbit pyrogen test (RPT) and transition to modern, animal-free alternatives. This shift is guided by ethical imperatives on the protection of animals used for scientific purposes and grounded in state-of-the-art scientific innovation, with a strong focus on enhancing patient safety.

Since then, all references to the RPT have been deleted from Ph. Eur. texts, with an implementation date of 1 July 2025, and the dedicated RPT chapter will be officially suppressed as of 1 January 2026. Rather than prescribing a single replacement test, the Ph. Eur. has introduced a new general chapter, 5.1.13. Pyrogenicity, which places the on users to select the most appropriate pyrogenicity testing strategy based on scientific justification and a risk assessment.

Among the available alternatives, the monocyte activation test (MAT) is rapidly gaining ground as a scientifically robust, animal-free method.

We are pleased to invite you to a follow-up symposium that will:

  • provide updates on the implementation of the RPT phase-out strategy across Europe;
  • explore the challenges and solutions encountered during the transition to MAT;
  • share insights into how other pharmacopoeias and regulatory frameworks outside Europe to the Ph. Eur.’s initiative;
  • bring forward perspectives from regulators, industry, and international stakeholders on the future of animal-free pyrogenicity testing.

The symposium will also offer an opportunity for participants to familiarise themselves with the current use of recombinant reagents, such as recombinant Factor C

SAVE THE DATE! The symposium will take place at the Albert Borschette Conference Centre (CCAB) in Brussels (Belgium) on 25-26 February 2026. While the event will be held in a hybrid format, in-person participation is strongly encouraged to facilitate engagement and networking opportunities.

More information on the programme and how to register for this event will be published soon.

You may also be interested to read more about: